ERBB2 and breast cancer: While CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have transformed treatment for metastatic HR<sup>+</sup>/HER2<sup>-</sup> BC, acquired resistance remains a major obstacle.